2023
Abstract LB237: Functional characterisation of TRACERx reveals mechanisms of NSCLC evolution
Lu W, Zalmas L, Bailey C, Pich O, Ruiz C, Black J, Stavrou G, Biswas D, Gimeno-Valiente F, Litchfield K, Bartek J, McGranahan N, Kanu N, Swanton C. Abstract LB237: Functional characterisation of TRACERx reveals mechanisms of NSCLC evolution. Cancer Research 2023, 83: lb237-lb237. DOI: 10.1158/1538-7445.am2023-lb237.Peer-Reviewed Original ResearchNon-small cell lung cancerElevated chromosomal instabilityWhole-genome doublingChromosomal instabilityIntratumoral heterogeneityHomologous recombination repairDNA damage responseAmerican Association for Cancer Research annual meetingsPC9 cellsRates of acquired resistanceIncreased intratumoral heterogeneityCell lung cancerIncreased CINDrug-resistant tumorsGenome doublingFunctional characterisationStructural chromosome instabilityWhole-genome doubling eventsFAT1 mutationsHomologous recombination repair pathwayBRCA1 foci formationChromosomal gainsMitotic error rateTargeted therapySolid tumors
2022
Abstract 5636: V-delta-1 T cells are resident in the human lung and associate with survival in patients with non-small cell lung cancer in the TRACERx Study
Wu Y, Biswas D, Usaite I, Mihaela A, Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J, Reading J, Georgiou A, Al-Bakir M, McGranahan N, Jamal-Hanjani M, Hackshaw A, Consortium T, Quezada S, Hayday A, Swanton C. Abstract 5636: V-delta-1 T cells are resident in the human lung and associate with survival in patients with non-small cell lung cancer in the TRACERx Study. Cancer Research 2022, 82: 5636-5636. DOI: 10.1158/1538-7445.am2022-5636.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerT cell compartmentV delta 1T cellsAssociated with survivalLung cancerTRACERx studyLung tissueAmerican Association for Cancer Research annual meetingsStage I-III non-small cell lung cancerT cell knockout miceCD8+ T cellsMurine tissuesFirst-in-human clinical trialIL-17-producingNon-malignant lung tissueT-cell immunotherapyT-cell receptor sequencingT cell clonesIL-17 productionT helper 1Acute myeloid leukemiaSusceptibility to carcinogenesisHuman lungAbstract 645: Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study
Hiley C, Litchfield K, Pich O, Moore D, Naceur-Lombardelli C, Veeriah S, Bakir M, Summan S, Grigoriadis K, Ruiz C, Puttick C, Enfield K, Ward S, Frankell A, Biswas D, Rosenthal R, Birkbak N, Jamal-Hanjani M, McGranahan N, Swanton C, Consortium T. Abstract 645: Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study. Cancer Research 2022, 82: 645-645. DOI: 10.1158/1538-7445.am2022-645.Peer-Reviewed Original ResearchNon-small cell lung cancerTumor mutational burdenIntra-tumor heterogeneityIntratumoral heterogeneityCancer Cohort StudyImmunotherapy biomarkersTumor regionAmerican Association for Cancer Research annual meetingsPredictors of response to immunotherapyCohort studyPrediction of immunotherapy responseTumor purityNeo-adjuvant settingResponse to immunotherapyFirst-line therapyImpact of intratumoral heterogeneityCell lung cancerMisclassification of patientsWhole-exome sequencingHeterogeneity of expressionMetastatic settingPDL1 immunohistochemistryPrimary tumorImmunotherapy responseMutational burdenAbstract LB064: B cells synergize with T cell regulation at immune hotspots in lung squamous cell carcinoma
Zhang H, AbdulJabbar K, Moore D, Akarca A, Enfield K, Jamal-Hanjani M, Raza S, Veeriah S, Biswas D, Salgado R, McGranahan N, Quesne J, Swanton C, Marafioti T, Yuan Y. Abstract LB064: B cells synergize with T cell regulation at immune hotspots in lung squamous cell carcinoma. Cancer Research 2022, 82: lb064-lb064. DOI: 10.1158/1538-7445.am2022-lb064.Peer-Reviewed Original ResearchTertiary lymphoid structuresSquamous cell carcinomaLung squamous cell carcinomaCD8+ T cellsCell carcinomaT cell regulationB cellsT cellsTumor nestsAmerican Association for Cancer Research annual meetingsLymphoid aggregatesTumor-infiltrating CD8+ T cellsPresence of tertiary lymphoid structuresCD4+Foxp3+ T cellsAssociated with poor overall survivalSubpopulation of T cellsHeterogeneous immune infiltrationT regulatory cellsRobust prognostic markersImmune cell aggregatesT cell subtypesT cytotoxic cellsTherapeutic targetImmune cell subpopulationsPoor overall survival